22:05 , May 17, 2019 |  BC Extra  |  Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate. Kairos Ventures led the round, with participation...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of...
17:56 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...